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Introduction 
 
Ribosomally synthesized and post-translationally modified peptides 
Antimicrobial peptides produced by all multicellular organisms as a first line of defense 
have often been shown an impact on human health1. Countless antibacterial, anticancer and 
antifungal therapeutics have been developed on the basis of these biologically active molecules2. 
Depending on whether their biosynthesis is ribosome dependent or independent, these natural 
products can be classified into two main categories3. Those produced by non-ribosomal 
polypeptide synthetases (NRPS) are the most broadly studied and include well-known antibiotics, 
such as vancomycin or bacitracin, which have been widely used over the past 50 years to treat 
different types of bacterial infections. The family of ribosomally-synthesized and post-
translationally modified peptides (RiPPs) is in rapid expansion. Recent advancements in genome 
sequencing and bioinformatics have decreased costs, resulting in a vast increase to the amount of 
genomic data available. Due to the degree of complexity and diversity of most of these peptides, 
RiPPs were initially believed to be non-ribosomal peptides, which are assembled by large multi-
modular enzymes. Their biosynthetic pathways are instead comparatively simple, and the 
structural diversity is introduced by extensive post-translational modifications. These 
modifications can be predicted with relative ease from the sequence homology of genes clustered 
around the peptide. The RiPP is initially synthesized as a short, unmodified peptide, together with 
several modifying enzymes and transporters to excrete the product after the modifications 
occurred4. The structure of the peptide operons is very similar across different organisms and share 
similar features that can be summarized. The key common component (Fig. 1) is the presence of 
a so-called “leader peptide” recognition sequence at the N-terminus or, more rarely, at the C-
terminus (“follower peptide”). Typically, the biosynthesis starts with the synthesis of a longer 
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precursor peptide encoded by a structural gene, which includes the recognition sequence attached 
to the “core peptide”, the linear and unmodified form of the RiPP. The core peptide is then post-
translationally modified by a variable number of enzymatic reactions and usually after all the 
modifications are completed, the recognition sequence is proteolytically removed and the mature, 
bioactive form of the peptide is exported. 
 
Overview of different structural features 
Ribosomally-synthesized and post-translationally modified peptides with highly variable 
structures have been isolated from a variety of organisms. In reviewing the most interesting ones, 
it is worth mentioning the extremely cytotoxic polytheonamides, which belong to the proteusins 
family. Isolated from the marine sponge Theonella swinhoei, Polytheonamide A and B are 
complex peptides formed by 48 modified amino acids, with the peculiar presence of several tert-
leucines, C-methylated amino acids and the almost perfect alternation of L- and D-configured 
Figure 1. Ribosomally synthesized and post-translationally modified peptides general biosynthetic pathway. 
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residues5. One of the remarkable aspects of their biosynthetic pathway is the presence of only six 
candidate enzymes in the entire 14kb gene cluster responsible for the 48 modifications (Fig. 2). 
Other examples of interesting structures from different organisms are the cyanobactins from 
cyanobacteria6, N-to-C macrocyclic peptides usually produced when the bacteria are in symbiosis 
with another organism; the microcins produced by Enterobacteriaceae, very small peptides (<10 
kDa), almost always encoded in plasmids7; the bottromycins found in common Streptomyces, 
containing a macrocyclic amidine and a decarboxylated C-terminal thiazole8. Very frequently, 
cysteine residues are involved in post-translational modifications, as thiols are readily converted 
to disulfides or thiazol(in)es for instance. Based on gene frequency in publicly available databases 
(NCBI, EBI, JGI, etc.), the most abundant RiPPs are in fact lanthipeptides, a distinct family of 
molecules with cysteine thioether crosslinks as their unique post-translational modification. To 
form this bond, dehydration of Ser or Thr leads to 2,3-didehydroalanine (Dha) or 2,3-
didehydrobutyrine (Dhb) respectively, which can act as Micheal acceptors in a 1,4-conjugate 
addition with a cysteine residue nerby (Fig. 3A)4. Tautomerization of the resulting enolate 
completes the formation to a lanthionine (Lan, from Ser) or methyllanthionine (MeLan, from Thr) 
thioether crosslink. Depending on the enzymes responsible for the post-translational 
Figure 2. Polytheonamides structure. Structure of the polytheonamides A and B. 
They differ on the configuration of the methionine sulfoxide at pos. 45. 
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modifications, the lanthipeptides are divided in four classes (I-IV). Compounds that exhibit 
antimicrobial activity are classified as lanthibiotics. One of the first RiPP discovered was the 
lanthibiotic nisin, first isolated in 1928, and structurally fully elucidated in 19719. Nisin A (Fig. 
3B) contains five thioether crosslinks, each forming a ring of different size along the chain. 
Notably, thioether formation and ring closure result in re-protonation of the α-carbon at either the 
re- or si-face of the Lan or (Me)Lan residue, restoring or inverting the stereochemistry of the 
original amino acid. It is postulated that these stereochemical inversions, cyclizations or other 
modifications are common among all RiPPs, as they increase the metabolic stability of the peptide 
and decrease its conformational flexibility. 
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Sactipeptides 
A different type of post-translational modification 
containing sulfur from cysteine residues is found in 
sactipeptides. This smaller group of more recently discovered 
RiPPs presents a characteristic crosslink between the sulfur of 
a Cys residue and the α-carbon of another residue. Given the 
strong antimicrobial activity and unifying structural features, the class has been named sactibiotics, 
from sulfur to alpha-carbon (or thioether cross-linked) antibiotics. This bond was already known 
to be present in some non-ribosomally synthesized diketopiperazine derivatives, such as gliotoxin 
(Fig. 4), formed by the nucleophilic attack of glutathione on a diketopiperazine N-acyl imine 
intermediate10. However, since it is NRPS-derived and involves a disulfide bridge, this 
modification differs from the new class introduced. To date, only seven sactipeptide natural 
products have been isolated or reported, six of which in Bacillus species and one in staphylococci. 
Subtilosin A (SboA) has been the first sactibiotic to be reported in 2003 by Vederas et al11. It is 
also the most well studied peptide of this family, as in the last 15 years several groups have shared 
efforts towards its understanding, from structure elucidation to the mechanism of action of its 
antimicrobial activity. 
 
AlbA — Subtilosin A 
Subtilosin A (Fig. 5) is encoded by the sbo-alb operon of Bacillus subtilis. It is initially 
ribosomally-synthesized as a linear 43-residue peptide and it undergoes several sequential post-
translational modifications, before it is ultimately exported outside the cell membrane in its mature 
form, a circular head-to-tail 35-residue peptide. One of the key steps of its biosynthesis is carried 
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Figure 4. Structure of gliotoxin. 
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out by the radical S-adenosylmethionine (SAM) enzyme AlbA, which catalyzes the formation of 
three sulfur to α-carbon thioether bonds on the initial linear moiety, between the cysteines C4, C7, 
C13 and three other residues F31, T28, F22 respectively12. The operon of each sactipeptide 
reported contains at least one orf encoding a radical SAM enzyme. These enzymes have been 
demonstrated to be responsible for the formation of the signature thioether bond, and they are 
therefore called sactisynthases. Radical SAM enzymes form a large superfamily containing over 
100,000 homologous members that catalyze a number of different transformations, including 
metabolism, nucleic acid modification and biogenesis of cofactors13. 
The members of this family are characterized by the presence of a CXXXCXXC motif, 
where the three cysteine thiolates coordinate three iron atoms of a [4Fe-4S]2+/+ cluster required for 
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Figure 5. Subtilosin A. A. Structure of subtilosin A. In bold the leader peptide sequence, in red and green the 
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several post-translational modifications. 
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Figure 6. Radical SAM reaction scheme. General reaction scheme for radical S-adenosylmethionine enzymes. 
5’-deoxyadenosine radical can now abstract a hydrogen from a non-reactive position. 
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catalytic activity. The remaining iron coordinates a molecule of S-adenosylmethionine, which, 
upon a single electron transfer from the reduced form of the Fe-S cluster ([4Fe-4S]+), it cleaves 
generating 5’-deoxyadenosine radical (5’-dA⦁) and methionine, restoring the oxidized form of the 
cluster (Fig. 6). The cluster reduction from +2 to +1 requires low-potential electrons, which in 
vitro can often be successfully provided by NADPH/flavodoxin/ferredoxin systems or chemical 
reducing agents, such as sodium dithionite or titanium(III) citrate. The 5’-deoxyadenosine radical 
is then responsible for a variety of different reactions, typically activating aliphatic groups or other 
chemically inert positions. Moreover, for several radical SAM enzymes, the presence and function 
of auxiliary iron-sulfur clusters have been described. Two of the most remarkable examples of this 
category are BioB14, the enzyme responsible for the last reaction of the biotin biosynthetic 
pathway, which contains a [2Fe-2S]2+/+ cluster in addition to the main [4Fe-4S]2+/+, and LipA, 
involved in lipoic acid biosynthesis, which contains an auxiliary [4Fe-4S]2+/+ cluster instead15. 
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Figure 7. BioB, LipA, RimO. BioB, LipA and RimO reaction schemes. The auxiliary cluster they 
coordinate is indicated below the arrow. In red the hydrogens abstracted by 5’-dA⦁, in blue the sulfur atom 
from the Fe-S auxiliary cluster incorporated into the final product. 
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Following a similar mechanism, these two enzymes incorporate one (BioB) or two (LipA) sulfur 
atoms from the secondary cluster into their final product. For each sulfur to carbon bond, a 
hydrogen radical abstraction occurs, and thus one equivalent of SAM is required. LipA generates 
two sulfur-carbon bonds with two sulfur atoms, whereas BioB incorporates one sulfur atom into a 
thioether, closing a five-membered ring. Similar sulfur incorporation from auxiliary clusters is 
observed in methylthiotransferases, such as RimO and MiaB16, where SAM first donates the 
methyl group to the sulfur of the cluster, which then reacts with the radical substrate to form a 
carbon-SCH3 bond (Fig. 7). 
In subtilosin A biosynthesis, AlbA contains 
two [4Fe-4S] clusters, with the second cluster 
most likely coordinated by a set of cysteines 
(C408, C414, C417) near the C-terminus. This 
domain is conserved within the subcategory of 
radical SAM enzymes classified as “SPASM 
and twitch domain-containing” maturases, 
where SPASM is an acronym for subtilosin, 
pyrroloquinoline quinone, anaerobic sulfatase 
and mycofactocin, the first natural products 
discovered to have a key step carried out by a 
protein from this family17. This domain is 
characterized by the presence of an additional 
variable cysteine motif near the C-terminus, 
usually involved in binding the auxiliary Fe-S Figure 8. AlbA, proposed mechanism. Proposed mechanism for SboA thioether crosslink formation. 
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cluster(s). More specifically, a Twitch domain is a truncated version of the SPASM domain, 
containing no more than one auxiliary cluster. 
For AlbA, in the sulfur to α-carbon crosslink formation mechanism, the substrate SboA is proposed 
to coordinate the auxiliary Fe-S cluster (Fig. 8). The first cluster would be responsible for SAM 
cleavage activity, forming a 5’-dA radical, which abstracts the α-hydrogen of a phenylalanine or 
threonine, and the carbon-centered radical would then form the thioether bond with the coordinated 
substrate cysteine, with the auxiliary Fe-S cluster acting as the electron acceptor.  
 
ThnB — Thuricin H 
The same research group proposed a similar mechanism for the radical SAM enzyme 
ThnB, in the biosynthesis of thuricin H18,19, a 31-residue bacteriocin isolated from Bacillus 
thuringiensis SF361. In this case, the precursor peptide ThnA undergoes formation of four 
different thioether crosslinks (Fig. 9). Interestingly, ThnB and AlbA share homologies in the N-
terminal region with PqqD, an enzyme involved in pyrroloquinoline quinone cofactor (PQQ) 
biosynthesis. PqqD is proposed to be a peptide chaperone, forming a complex with the radical 
SAM enzyme PqqE, responsible for the formation of a C-C bond between the carbon in the ortho 
position to the phenol of a tyrosine residue and the γ-carbon of a glutamate residue. Marahiel’s 
group has shown how a ThnB construct not containing this PqqD-like portion is still able to cleave 
S-adenosylmethionine, but not to catalyze the thioether crosslink. This led to proposing how, even 
without containing an active site, this region might be fundamental for substrate recognition and 
METPVVQPR - DWTCWSCLVCAACSVELLNLVTAATGASTAS
MKKAVIVE - NKGCATCSIGAACLVDGPIPDFEIAGATGLFGLWG
Figure 9. Thuricin H. 
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binding, or for substrate positioning with respect to the second Fe-S cluster. Another hypothesis 
could be that the auxiliary clusters do not actively participate in the reaction, but they only move 
electrons from a reducing agent to the active site, which, in this case, would be the main radical 
SAM cluster. This mechanism is common for other proteins20. 
 
SkfB — Sporulation Killing Factor 
The Sporulation Killing Factor (SKF) presents similar features to SboA and thuricin H. It 
is a 26-residue circular sactipeptide produced by Bacillus subtilis 168, which shows two post-
translational modifications: a thioether linkage between Cys4 and Met12, and a disulfide bond 
between Cys1 and Cys16 (Fig. 10)21. The expression of its precursor SfkA is increased during 
limited nutrient conditions and, after modification and export from the cells, the peptide induces 
lysis or inhibits further growth of other microbial species. SfkB is the enzyme responsible for the 
formation of the C4-M12 thioether bond and it shows sequence homology with AlbA and ThnB, 
including the PqqD-like domain. The mechanism proposed for SfkB is equivalent to the enzymes 
containing auxiliary [4Fe-4S] described previously. This system is a good model for mechanistic 
studies of sactibiotic biosynthesis, as there is only one Cys to α-carbon crosslink formed. In 
addition to the experiments already mentioned, Marahiel et al. investigated SfkB specificity 
toward the donor and acceptor amino acid. The donor amino acid has to be a cysteine and does not 
react if exchanged into a serine, whereas the acceptor amino acid seems to be more flexible. More 
specifically, hydrophobic and aromatic amino acids are always tolerated as acceptors, small 
METPVVQPR - DWTCWSCLVCAACSVELLNLVTAATGASTAS
MKKAVIVE - NKGCATCSIGAACLVDGPIPDFEIAGATGLFGLWG
MKRNQKEWESVSKKGLMKPGGTSIVKAAG - CMGCWASKSIAMTRVCALPHPAMRAI
S S
Figure 10. Sporulation Killing Factor. 
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hydrophilic ones (Ser, Thr, Asp) can form the thioether bond in lower yields, and larger hydrophilic 
amino acids (Glu, Gln, Lys) are unreactive. This led to the conclusion that the radical α-hydrogen 
abstraction is independent of the amino acid nature, and only the second part of the mechanism 
dictates whether the cysteine will form the crosslink, or the radical substrate will abstract another 
hydrogen. Moreover, in all three enzymes AlbA, ThnB and SkfB, the thioether bond formation 
does not occur without the presence of the leader peptide sequence, suggesting that post-
translational modification occurs prior to proteolysis. In 2018, Drennan et al. reported the crystal 
structure of SkfB22, showing the secondary structure of the radical SAM domain, very similar to 
most enzymes of this family. In contrast to the hypothesis made by the Marahiel group, the crystal 
structure surprisingly shows the presence of a [2Fe-2S] cluster in the Twitch C-terminal domain 
(Fig. 11). Previously, PqqE had been shown to contain a [2Fe-2S] cluster17, but SfkB is more 
homologous to members of the sactisynthase family, hypothesized to always contain [4Fe-4S] 
clusters. Similarly to PqqE, SfkB binds this auxiliary cluster into a CX33CXC motif, where the two 
Figure 11. SkfB crystal structure. A. SkfB radical SAM domain [4Fe-4S] cluster; B. the [2Fe-2S] auxiliary 
cluster coordinated by SkfB Twitch domain.  
 
A B 
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nearly adjacent cysteine residues coordinate the same iron atom. Supporting the mechanism 
proposed for SboA, Drennan also discusses how this auxiliary [2Fe-2S] cluster could be potentially 
coordinated by the peptide and participate to the reaction, but, unfortunately, no crystal structure 
for a sactisynthase complex with its peptide has been reported. 
 
Tte1186 — Tte1186a 
An alternative mechanism has been proposed for the sactisynthase Tte1186 and its 
sactipeptide Tte1186a by Bandarian et al23. This enzyme is reported to contain three [4Fe-4S] 
clusters and, through mutation studies, it has been shown that in the absence of any of the two 
auxiliary clusters the reaction does not occur, even while cleavage of SAM does. The peptide 
contains six cysteines, but in vitro, the formation of only one crosslink was observed. Bandarian 
discusses the mechanism proposed by Marahiel, focusing on how the coordination of the 
secondary cluster to the substrate might be reasonable, but is not consistent with the 
stereochemistry of the final product. A majority of the sactipeptides that have been reported have 
multiple crosslinks, and the new carbon-sulfur bond forms with retention of stereochemistry at 
some centers and inversion at others. This stereochemical variability indicates that the radical 
intermediate likely can be attacked at either the si- or re-face. If this is the case, it has to be possible 
for the α-carbon radical to be attacked at the position initially occupied by the α-hydrogen (for 
crosslinks that occur with retention of configuration) or at the opposite face (in case of inversion). 
Assuming that the 5’-dAH does not dissociate from the active site until the end of the reaction, the 
face previously occupied by the α-hydrogen would be occluded by 5’-dAH, and a thiolate attack 
from this face would require the radical intermediate to be relatively flexible and rotate to expose 
this face. However, this option seems unreasonable, since the data available for radical SAM 
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enzymes shows how H-atom donor and acceptor are always within Van der Waals contact and 
movement of the radical intermediate is most likely limited and controlled by the active site. 
Therefore, Bandarian proposes not the direct formation of a thioether bond between Cys and α-
carbon, but instead the conversion of the α-carbon radical to a more stable and planar intermediate, 
probably an acylimine or acylimminium, with the radical electron transferred to the auxiliary Fe-
S cluster (Fig. 12). This intermediate could be attacked by the thiolate from either face. Bandarian’s 
mechanism is analogous to the lanthionine bond formation in lanthipeptides4, wherein an activated, 
planar amino acid intermediate is formed and regioselectivity is imposed by the enzyme through 
conformation of the active site.  
 
Hyicin 4244 and thermocillin 
Although they have not been studied as thoroughly as the other peptides described, two 
more examples have been recently added to the sactipeptides family and are worth mentioning. In 
2018, Bastos et al. reported the bacteriocin Hyicin 4244 as the first sactibiotic produced by 
The linked image cannot be displayed.  The file may have been moved, renamed, or deleted. Verify that the link 
points to the correct file and location.
Proposed mechanisms of thioether cross-link formation in lantipeptides and sactipeptides. (A) Mechanism of thioether cross-link formation in lanthipeptides. Substrate is activated to generate a reactive intermediate (Dha or Dhb), which undergoes Michael
Published in: Nathan A. Bruender; Jarett Wilcoxen; R. David Britt; Vahe Bandarian; Biochemistry 2016, 55, 2122-2134.
DOI: 10.1021/acs.biochem.6b00145
Copyright © 2016 American Chemical Society
Figure 12. Thioether cr sslink formation, mechanism proposed by Bandarian et al. 
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staphylococci24, making it the first produced by any organism other than a gram-positive spore-
forming bacillus. The hyicin operon is very similar to those of subtilosin A and other members of 
the family, containing radical SAM enzyme, ABC transporter and peptidase genes among others. 
Unfortunately, the Bastos group has not been able to isolate the bacteriocin yet, nor any of the 
enzymes of the gene cluster. From gene sequence alignment, Hyicin 4244 is predicted to be very 
similar to subtilosin A structurally. Additionally, all the enzymes in its biosynthetic gene cluster 
show at least 42% sequence identity with the enzymes of the sbo-alb operon. This will be a very 
interesting molecule to isolate and study in the future, since concentrated biological samples 
showed the inhibition of biofilm formation in 14 staphylococci strains isolated from human 
infections and bovine mastitis. Hyicin 4244 has potential to become an antimicrobial for 
prevention or treatment of biofilm-related infections caused by several different staphylococci.  
Moreover, thermocellin (cte) is a predicted natural product of the bacteriocins family from 
Clostridium thermocellum ATCC 27405, but it has not been successfully isolated yet. Bowers et 
al. have been able to heterologously express and purify its precursor peptide CteA and the 
sactisynthase CteB25. As for Tte1186a, CteA contains six cysteine residues, so presumably the 
natural product would contain six thioether crosslinks, since all sactipeptides reported so far are 
modified at each cysteine. However, the Bowers group was able to form only one thioether 
crosslink in vitro. The crystal structure of CteB shows the presence of two additional [4Fe-4S] 
clusters in the C-terminal domain, for a total of three clusters. Again, due to failed attempts in co-
crystallization, there is no structure with full length CteA bound. Though, they were able to 
crystallize CteB with an N-terminal 21-residue truncation (CteA 1-21). According to the Bowers 
group, the binding position of this shorter peptide within CteB and the open coordination site of 
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one of the two auxiliary clusters imply that Marahiel et al. were right in proposing how the 
substrate coordinates to one of the auxiliary clusters. 
 
Quinohemoprotein amine dehydrogenase γ-subunit 
The final member of the sulfur to α-carbon crosslinks class is the small (~9kDa) 
quinohemoprotein amine dehydrogenase (QHNDH) γ-subunit QhpC26. This is a unique addition 
to the family, in that this protein is the subunit 
of a larger protein complex and not a peptide 
natural product. This implies that these 
thioether crosslinks are not just present in 
antimicrobial peptides, but they can be 
involved in other metabolic and constructive 
pathways as well. The radical SAM enzyme 
QhpD is responsible for the formation of three linkages in QhpC, on two Asp and one Glu residue. 
These bonds slightly differ from those of the sactipeptides previously described, in that they are 
sulfur to β-carbon crosslinks (Fig. 13), but the hydrogen homolytic abstraction step requires to 
overcome a higher bond dissociation energy: ~400 kJ/mol in QhpC vs. <350 kJ/mol for the 
sactipeptides described. QhpD coordinates three [4Fe-4S] clusters, all required for its activity. The 
mechanism proposed by Okajima et al. is equivalent to the one described for subtilosin A; 
however, in this case, QhpD forms a stable complex with QhpC (QhpD⦁QhpC). Mutation of any 
of the QhpD cysteine residue to Ser not only abolishes activity, but also drastically decreases the 
stability of the QhpD⦁QhpC complex. This raises the hypothesis of a role of the auxiliary [4Fe-
4S] clusters in substrate binding.  
H
N
SH
HN O
H
NO
O-
O
QhpD
H
N
S
HN O
H
N
O
-O
O
H
Figure 13. QhpD reaction scheme. Cysteine to β-
carbon crosslink formation in QHNDH γ-subunit, 
mediated by QhpD. 
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Thuricin CD 
One of the most well characterized sactibiotics to date is thuricin CD. Thuricin CD is a 
two-component bacteriocin, formed by two 30-residue subunits Trnα and Trnβ. These two peptides 
both contain three thioether crosslinks, specifically between Cys 5, 9, 13 and Thr 28, 25, Ser 21 
respectively in Trnα, and Cys 5, 9, 13 and Tyr 28, Ala 25, Thr 21 in Trnβ, forming the sactibiotic 
secondary structure, which is most likely crucial for its bioactivity (Fig. 14). Thuricin CD was first 
isolated from Bacillus thuringiensis by Rea et al. in 201027, who, during the search for a potent 
narrow-spectrum antibiotic against Clostridium difficile, hypothesized that, in the presence of this 
bacterium, spore-forming anaerobic bacteria in the human gut would produce bacteriocins as a   
defense mechanism. Screening of over 30,000 fecal samples from healthy and diseased adults 
yielded only one colony with considerable activity. This colony was purified, grown in rich media 
and designated as Bacillus thuringiensis DPC 6431. Furthermore, the active natural product 
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bacteriocin thuricin CD was isolated and characterized for the first time. The peptide shows little 
activity against almost all Gram-positive bacteria tested, but high potency against C. difficile, with 
an activity at least equivalent to commonly used antibiotics. This discovery makes thuricin CD a 
very strong candidate as a new narrow-spectrum drug against C. difficile. 
 
Clostridium difficile and CDAD 
C. difficile was defined as the causative agent of nosocomial diarrhea in 1978. This 
pathogen has become more common and dangerous each year globally, particularly with the 
appearance of a hypervirulent strain NAP1/BI/027, which developed in North America in the past 
decade28. It is strongly resistant to most common prescribed antibiotics, therefore it flourishes in 
the human gut as much of the beneficial flora is eradicated during wide-spectrum antibiotic 
therapy. It follows that, contracting an infection is easy in hospital environments, and immune 
compromised patients that come in contact with this pathogen will often develop Clostridium 
difficile-associated disease (CDAD). CDAD is an infection affecting almost half a million patients 
a year in the United States, with clinical illness ranging from mild diarrhea to fulminant colitis and 
death29. Around 30,000 deaths are associated to its diagnosis each year, with 80% of fatalities in 
patients over 65 years of age30. The transmission with this bacterium is primarily person to person, 
or by fecal-oral route and environmental contamination31; recent reports in Europe have also 
registered an increase in CDAD infections originating from animal reservoirs, such as the ribotype 
087 strain of C. difficile (currently the second most common strain to cause human infections), 
which is often harbored in pigs28. The most commonly used antibiotics for CDAD treatment are 
metronidazole and vancomycin, both of which dramatically increase the abundance of organisms 
of the phylum Proteobacteria at the expense of organisms of other phyla32. Thuricin CD shows a 
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slightly weaker bioactivity compared to metronidazole, but it markedly improves the effect on the 
biodiversity of the gut microbiota (Fig. 15), making this peptide the most suitable antibiotic against 
C. difficile known to date. A better understanding of its structure and biosynthetic pathway would 
inform efforts towards a biological method of production and aide in advancing clinical trials. The 
putative thuricin CD operon shows the same basic structure as subtilosin A and the other 
sactipeptides described (Fig. 16): two complete and overlapping orfs named trnC (1521 bp) and 
trnD (1245 bp) show homologies to the radical SAM superfamily and are thought to be responsible 
for the thioether crosslink formation; trnF and trnG genes are homologous to ATP binding cassette 
(ABC) transport proteins and together they are thought to form a translocation complex, with TrnF 
Figure 15. Metronidazole vs. thuricin CD. A. Comparison between metronidazole and thuricin CD after 24 
hours incubation in a human colon infection model. B. Effect of metronidazole and thuricin CD on the 
composition of the gut microbiota, here depicted at the phylum level. 
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Figure 16. Thuricin CD gene cluster. 
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functioning as C-terminal ATP-binding domain, and TrnG as N-terminal hydrophobic integral 
membrane domain (since it includes six transmembrane α-helices)33. In 2014, Ross et al. identified 
an additional orf named trnI and located upstream of trnF34, which encodes a small transmembrane 
protein that affords the producing microbe with resistance against thuricin CD; trnE shows 
homology to C-terminal processing peptidases; and finally, between trnF/G and trnC/D are located 
the two orfs trnA and trnB, encoding the precursor peptides to Trnα and Trnβ. TrnA and TrnB 
amino acid sequences are very similar, with a leader peptide of 17 and 19 residues respectively, 
followed by a Gly-Gly sequence and the core peptide, for a total of 47 and 49 residues (Fig. 17). 
Interestingly, the GG motif, which is commonly present in ribosomally synthesized bacteriocins, 
is usually cleaved by a protease after the second glycine. However, in thuricin CD the cleavage 
happens between the two residues. Assuming an equivalent biosynthetic pathway to the other 
members of the sactipeptide family, thuricin CD is proposed to be synthesized as a linear precursor 
peptide, which undergoes thioether crosslink formation by TrnC and TrnD as the first post-
translational modification, followed by cleavage of the leader sequence by TrnE peptidase. The 
subsequent transport and excretion of the mature peptide is mediated by TrnF and TrnG (Fig. 18).  
Vederas et al. reported multidimensional NMR studies, isolating thuricin CD from fermented B. 
thuringiensis in [13C, 15N] fully labeled rich media35. Through NMR studies and calculation of the 
most optimal stereoisomers, the authors determined the stereochemistry of the amino acids 
involved in the thioether crosslinks. Interestingly, both peptides show an R-configuration in two 
of the crosslinks and a S-configuration in the third one, Thr28 in Trnα and Tyr28 in Trnβ. Since 
thuricin CD is the first case of a sactipeptide with two orfs for two separate radical SAM enzymes 
in its gene cluster, this finding raises several questions about the mechanism of formation of 
thioether bond formation, the order in which they form, the specific role of each enzyme and how 
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thuricin CD biosynthesis differs from the other members of its family. When target bacteria are 
treated with a single peptide subunit, Trnβ is 10 times more active against C. difficile than Trnα. 
However, when Trnβ and Trnα are combined at an optimized ratio of 2:1 (forming thuricin CD), 
the bioactivity increases 100-fold, reaching a minimum inhibitory concentration (MIC)50 of 0.05 𝜇M, showing how the two peptides act in synergy. 
 
TrnA (47 residues):    MEVMNNALITKVDEEIGGNAACVIGCIGSCVISEGIGSLVGTAFTLG 
TrnB (49 residues):    MEVLNKQNVNIIPESEEVGGWVACVGACGTVCLASGGVGTEFAAASYFL 
 
Trnα:    GNAACVIGCIGSCVISEGIGSLVGTAFTLG 
        Trnβ:    GWVACVGACGTVCLASGGVGTEFAAASYFL 
 
 
Figure 17. Amino acid sequences of TrnA, TrnB, Trnα and Trnβ. 
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Figure 18. Thuricin CD, proposed biosynthetic pathway. 
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TrnC and TrnD 
Despite having general features similar to the other sactisynthases mentioned, with a 
CXXCXXXC motif at the N-terminus and the presence of several other cysteines near the C-
terminus SPASM domain, both TrnC and TrnD only show less than 20% sequence identity to 
AlbA. TrnC also shows sequence similarity to conserved domains of Fe-S oxidoreductase 
arylsulfatase regulatory proteins (AslB), whereas TrnD sequence is similar to enzymes in the 
MoaA family, which are involved in molybdopterin biosynthesis27. Given the stereochemical 
inversion on the last amino acid crosslink in Trnα and Trnβ, it is possible that one of these two 
enzymes is an epimerase and perhaps the other responsible for all three crosslinks. Alternatively, 
one could imagine that one enzyme generates two crosslinks and the third crosslink is installed by 
the second sactisynthase, possibly through a different mechanism, with inversion of the 
stereochemistry. The epimerase option is valuable, since post-translational epimerization 
generated by radical SAM epimerases in Bacillus species has been reported before36.   
Alternatively, since trnC and trnD genes are overlapping, another hypothesis is that the two 
proteins form an active complex (TrnC-D), wherein the separate proteins would not bind the 
substrate (TrnA or TrnB) until they assume a certain conformation via dimerization. This 
phenomenon is observed in the proteins PqqD and PqqE in the pyrroloquinoline quinone 
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Figure 19. TrnC and TrnD general reaction scheme. 
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biosynthetis pathway. Here, PqqD plays a role as peptide chaperon binding the peptide PqqA. This 
event then triggers the radical SAM enzyme PqqE to bind the PqqD-A complex and catalyze a C-
C crosslink formation37. 
 
TrnC (516 residues):  
MSKKRLSMMPFKTDKFSYALDGNTGRVIVADKPTLYIISHFHKFEKEELLKKTKGKFAELHQDYLTTYNYVSSLINM
GMFYLSEKEDSDSPIDSKELAINSNQSQLILILTEKCNLRCEYCIYNDKYPKEMGYSDEEMDFETAKKAVDMYYELH
MERVKRGHKRFPVITMYGGEPLLKFDLIKKVMEYAKGLMPDTLFYTTTNGTLLSEKMMDYFINNRIIITFSIDGFKE
NHDRNRVFVNGMPTFERAFKNIKRLQEKKKEQNIEQIISFNCCFDQYTDVYKVAKFFEEHYDLFNPFFVLYNQINPF
DTLYFDWCDEQVKTGKWNFDKNNFKNAMQKIEHELYEAETCDDHFQQVAGPLVMKDFVLSIRNKDGQQQITRNSCIP
TSKIAVSPDGTLTLCEKMCKKYPIGTVEKGLDWKAVDGVTEKLVRHFNSDSCKYCPIRTMCEACFMFLDENGRIKPS
FCKSKKMAVKKNLESYFAKKEKGFDVMKVYNHTSDLDSVKEMVK 
 
TrnD (414 residues):  
MKKYFRLYPYCHLEIGETNSCLYDISSGKMIRVNRENAELLRQCQENVPIESINMDLGILDELIKMNLGTYYANPQF
IEPFFETNDTKNRIFGKNNILRQMFILTSTDCNMNCKHCNTDSTVFRKTGCKIWPKSINLNALTQSHWRKILEAFYN
LHGEELTFIGGEPFLEFDFIKNIVEIAQEVGISKFSIFTNGSIINDTILNFLMENKIKVYIQIFEVDENKFKAFTNS
DIPSIQIIDNIKKLNNHHLDLQLRILITRDNDNNLKKIVNTLQKETNVKDIKIEFLYPKPDNSYYSKKYIPLMYDKK
REFSHVNVQKMQFLHQYNPSFFGQITIRRDGKVVPHPMLLTRVIGDLQQDDLFTIINTEEYQEYSTLNKEKISKCST
CAYKYNCMDDRVIENFATGDLYGMEYCNF 
 
 
 
 
 
 
 
 
 
 
Figure 20. TrnC and TrnD sequences. In blue, the CXXXCXXC motif. In red, other Cys present in the 
sequence. Near the C-terminus the Cys indicated are part of the SPASM domain and they might be 
coordinating auxiliary Fe-S cluster(s). 
 
 
 31 
Research Statement 
 
Considering the potential of thuricin CD as a drug, the aim of this project is to understand 
its biosynthesis, with the ultimate goal of producing the bacteriocin in large scale. To date, the 
mature bioactive peptide has been thoroughly characterized, but none of the enzymes responsible 
for the post-translational modifications have been studied at all. The two subunits forming the 
active peptide thuricin CD, Trnα and Trnβ, each feature three cysteine to α-carbon crosslinks. This 
unique structure is the hallmark of the sactipeptides family, a class of RiPP natural products 
counting only a few known members. These thioether crosslinks are known to be formed by radical 
S-adenosylmethionine enzymes, and while several mechanisms for installation of these bonds have 
been proposed, little enzymology data exists to support them. Usually, the sactipeptide operons 
contain one of these enzymes, which is responsible for one or multiple crosslinks. Thuricin CD is 
comprised of two different peptide subunits that works in synergy, and the gene cluster shows the 
presence of two radical SAM enzymes, whose specific functions are unknown. Heterologous 
expression in Escherichia coli, purification and initial characterization of TrnC and TrnD will be 
presented, in addition to methodology for the expression and purification of their substrates TrnA 
and TrnB, by way of a fusion protein system. Attempts to the understanding of the system will 
also be discussed, laying the groundwork for further investigations. 
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Materials and Methods 
 
TrnC/TrnD cloning 
Two pUC57 vector containing trnC and trnD genes were purchased and the two genes were 
cloned out and ligated into pET-28a(+) plasmids with traditional cloning procedures. The plasmids 
were transformed into E. coli BL21 Star (DE3) cells using the heat shock protocol. 
 
TrnC/TrnD expression  
The transformed cells were grown in lysogeny broth medium (LB, Fisher Scientific) 
containing 50 𝜇g/mL kanamycin, at 37°C, 225 rpm for 12-16 hrs. The cells were then transferred 
into culture flasks containing 1 L LB, 50 𝜇g/mL kanamycin and 5 mM ferric citrate and let grow 
at 37°C, 225 rpm. At an optical density (OD) of 0.5 (600 nm), the temperature was reduced to 
22°C and isopropyl-𝛽-D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.2 
mM. The cells were grown for 5-6 hrs, then harvested at 5,000 rpm for 10 min and frozen at -80°C.  
 
TrnC purification 
The cell pellets were resuspended in Buffer A (50 mM Tris/HCl, 0.5 M NaCl, 20 mM 
Imidazole, pH 8.0), transferred into a glass beaker and lysed using an ultrasonic homogenizer (two 
cycles, 2 min process time, 30 sec ON, 2 min OFF), then transferred into high speed centrifuge 
tubes. The lysate was centrifuged at 16,000 rpm for 1 h 10 min, the supernatant was kept, quickly 
transferred into a different tube and moved inside an inert atmosphere glove box, to minimize the 
oxygen exposure. The tube was opened inside the glove box and let incubate under nitrogen for 2 
hrs. TrnC was purified through gravity-flow Nickel-chelate chromatography (Ni-NTA), using 
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Qiagen Ni-NTA agarose resin (Qiagen). The column was equilibrated with 8 column volumes of 
Buffer A, the lysate containing TrnC loaded and the column washed thoroughly with Buffer A 
(>10 column volumes). A dark brown band was observed on top of the resin. The protein was 
eluted with Buffer B (50 mM Tris/HCl, 0.5 M NaCl, 300 mM Imidazole, pH 8.0) and the darkest 
fractions pooled together. Purification proceeded with iron-sulfur cluster(s) reconstitution. 
 
TrnD purification 
The cell pellets were resuspended in Buffer A (50 mM Tris/HCl, 0.5 M NaCl, 20 mM 
Imidazole, pH 8.0), transferred into a glass beaker, lysed and centrifuged using the same procedure 
described for TrnC. Since TrnD is more air-stable than TrnC, the purification process could be 
carried out in normal atmosphere. TrnD was purified by FPLC, using Ni-NTA agarose resin. The 
column was equilibrated at 5 mL/min with Buffer A, the lysate containing TrnD was then loaded 
at 2 mL/min and the column washed with Buffer A at 2 mL/min until the absorbance was stable at 
~0.2 AU. A dark brown band was observed on top of the resin. The protein was eluted with Buffer 
B (50 mM Tris/HCl, 0.5 M NaCl, 300 mM imidazole, pH 8.0) at 5 mL/min and the collected 
fractions concentrated using Amicon Ultra Centrifuge Filters 30k MWCO (Millipore). TrnD was 
then either reconstituted using the procedure described for TrnC or desalted through a P2 size-
exclusion resin (Bio-RAD) (elution buffer: 50 mM Tris/HCl, 5 mM 𝛽ME, 20% glycerol, pH 8.0). 
 
Fe-S cluster(s) reconstitution 
For longer storage time and iron and sulfur content analysis, TrnC and TrnD Fe-S clusters 
were reconstituted after Ni-NTA affinity chromatography. All required solutions (1 M 
dithiothreitol (DTT), 100 mM sodium sulfide (Na2S) and 100 mM ammonium iron citrate) were 
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freshly prepared with reconstitution buffer (25 mM Tris/HCl, 150 mM NaCl, 10 mM DTT, pH 
8.0). One hundred equivalents DTT were added to 50 𝜇M TrnC(D) and incubated at r.t. for 15 
minutes, followed by slow addition of 10 eq. of ammonium iron citrate, further 5 min incubation 
at r.t. and final addition of 10 eq. of Na2S. The resulting dark brown solution was incubated on ice 
overnight, then purified by gravity-flow size-exclusion chromatography, using Sephadex G-25 
Medium resin (GE Healthcare). Reconstitution buffer was used as final elution buffer, the darkest 
fractions were further concentrated down to the desired concentration, using Pierce PES 
concentrators, 10k MWCO (Thermo) and small aliquots frozen at -80°C, until further use. TrnC 
and TrnD were identified by sodium sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
 
Iron and sulfur content determination 
The iron content in TrnC and TrnD was determined following a modified version of Collins 
et al. analytical method38. A calibration curve was prepared from a 1000 mg/L iron standard stock 
solution (Sigma), with standards ranging from 5 to 25 nmol Fe. Considering the possible presence 
of 2 or 3 [4Fe-4S] clusters, the samples were prepared aiming for ~15 – 20 nmol Fe. Samples and 
standards were diluted to a volume of 500 𝜇L with Milli-Q H2O in 1.5 mL Eppendorf tubes and 
followed by addition of 450 𝜇L of 1 M HCl/10% trichloroacetic acid in H2O. The solutions were 
vortexed, incubated at 37°C for 30 min and any precipitate removed by centrifugation. The 
supernatant was transferred to clean tubes and 100 𝜇L of 10% (w/v) hydroxylamine•HCl were 
added; the samples were vortexed and 200 𝜇L of 4 mM 2,4,6-tripyridyl-s-triazine in H2O were 
added, followed by 150 𝜇L of 50% ammonium acetate. The samples were centrifuged at 14,000 
rpm for 10 min to remove any precipitate and the absorbance of each sample was read at 596 nm 
(ε596 = 22,600 M-1 cm-1). 
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Sulfur was determined using Beinert’s method for iron-sulfur proteins39. A calibration curve was 
prepared using Na2S•9H2O, ranging from 2 to 50 nmol S. Again, considering 2 or 3 [4Fe-4S] 
clusters, the samples were prepared aiming for ~20 – 30 nmol S. Samples and standards were 
diluted with H2O to a final volume of 200 𝜇L in a 1.5 mL Eppendorf tube, followed by addition of 
600 𝜇L of 1% (w/v) zinc acetate and 50 𝜇L of 7% (w/v) sodium hydroxide. The solutions were 
mixed by inversion, incubated at room temperature for 15 min and the precipitate centrifuged at 
3,000 rpm for 10 s. In the same tube, 150 𝜇L N-N’-dimethylbenzene-1,4-diamine (DMPD) (0.1% 
(w/v) in 5 M HCl) and 150 𝜇L FeCl3 (10 mM in 1M HCl) were added and the pellets resuspended 
by vortexing. The samples were incubated at r.t. for 20 min to allow the formation of methylene 
blue and the absorbance was measured at 670 nm (ε596 = 71,089 M-1 cm-1). 
 
Iron-sulfur clusters qualitative analysis 
In an inert glove box, the two proteins were transferred into an air tight cuvette at a 
concentration of 25-30 𝜇M. A full absorbance spectrum from 200 to 800 nm was recorded (Varian 
Cary 50 spectrophotometer). After addition of 100 equiv. of sodium dithionite, another full scan 
was recorded, and the two spectra compared. 
 
Titanium(III) citrate preparation 
Titanium(III) citrate was prepared according to Ghabbour40 procedure. A sure-sealed bottle 
of 10% TiCl3 in HCl (Sigma) was carefully moved into an inert atmosphere glovebox. In a round-
bottom flask, 500 𝜇L of TiCl3 were slowly added to 10 mL of a 0.2 M sodium citrate solution with 
continuous stirring. Sodium hydroxide was added dropwise until pH reached 8.0 and the solution 
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was used within a couple hours because prompt to fast oxidation. Titanium(III) citrate 
concentration was estimated to be ~80 mM. 
 
S-Adenosylmethionine cleavage assays 
The S-Adenosylmethionine (SAM) cleavage assays for TrnC and TrnD were carried out 
under anaerobic conditions in an inert atmosphere glovebox. All the stock solutions were brought 
into the box and incubated under nitrogen for about 1 hr. Three reducing systems were tested: 50 𝜇M Flavodoxin (Fld)/5 𝜇M Ferredoxin (FNR)/1 mM NADPH, 300 𝜇M sodium dithionite (DTN) 
or 10 mM titanium(III) citrate. The final volume for each assay was 200 𝜇L and the buffer used 
was 50 mM Tris/HCl, 0.1 M NaCl (pH 8.0). In order to further reconstitute the iron-sulfur clusters, 
25 𝜇M of TrnC or TrnD were incubated at r.t. for 15 min with 5 mM DTT, 250 𝜇M ammonium 
iron(III) citrate and 250 𝜇M sodium sulfide. In the case of Fld/FNR/NADPH reducing system, the 
two proteins were added with the reconstitution buffer and NADPH was added with SAM. The 
mixture was then incubated with 300 𝜇M SAM at r.t. for 15 min and finally, DTN and titanium 
citrate were added. Controls with no SAM, or no enzyme, or no reducing system were also carried 
out. The assays were run for 3-4 hrs, the proteins denatured with 10% sodium acetate pH 4.5, the 
reaction tubes placed on ice for 15-20 min and the precipitate spun down in a microcentrifuge at 
14,000 rpm for 10 min. The supernatant was analyzed by HPLC-MS. Chromatographic separation 
was performed on a T5-C18 column (Waters, 4.6 mm X 150 mm, 5 𝜇m) at 0.4 mL/min. The column 
was equilibrated in buffer A (1 mM NH4HCO2 in H2O, pH 3.5), and upon injection of 10 𝜇L of 
the sample, the reaction components were eluted with a linear gradient 0-20% buffer B (1 mM 
NH4HCO2 in 95:5 acetonitrile/H2O, pH 3.5) over 15 min. The assays spectra were quantified at 
260 nm and compared to a five point calibration curve of analytical standards (Sigma), 5’-
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deoxyadenosine (tR = 11.0 min) ([M+H]+ = 252.1). The ions were analyzed by an Agilent 6400 
triple-quadrupole mass spectrometer, equipped with an electrospray ionization (ESI) source, in 
positive mode. Nitrogen was the nebulizer drying gas (press. = 30 psi; flow rate = 7 L/min; temp. 
= 350°C). Additional parameters: spray capillary voltage = 3500 V; skimmer voltage = 65 V; 
fragmenter voltage = 100 V. Spectra were acquired over a 100-400 m/z range at 0.99 scan/s.		
MBP-TrnB-CBD cloning 
The vector pTWIN1 encoding the chitin binding domain (CBD) was purchased (NEB). A 
set of primers was designed in order to clone out of the plasmid the CBD gene, and another set to 
insert it at TrnB C-terminus, into the pMAL-c2x TrnB plasmid. After successful cloning, the 
pMAL-c2x TrnB-CBD plasmid was transformed into E. coli Rosetta (DE3) competent cells. 
 
MBP-TrnB and MBP-KR5/KR10-TrnB cloning 
A pUC57 vector containing trnA and trnB genes was purchased. The gene trnB was 
amplified and ligated following the manufacturer’s protocol into a modified pMAL-c2x plasmid 
(NEB), with a TEV protease cleavage site instead of the commercial Factor-Xa one. The plasmid 
was transformed into E. coli BL21 Star (DE3) cells using the heat shock method. The MBP-TrnB 
plasmid was also used as a template for KR5. The cloning was carried out aiming to introduce an 
additional five lysine/arginine residues at TrnB N-terminus. The MBP-KR5-TrnB plasmid was 
used as a template for KR10, with the purpose of introducing five more Lys/Arg. Every plasmid 
described was confirmed by agarose gel analysis and DNA sequencing transformed by heat shock 
into BL21 Star (DE3) cells. 
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MBP-TrnB, MBP-TrnB-CBD and MBP-TrnB/KR5/KR10 expression  
The transformed cells were grown in LB medium containing 50 𝜇g/mL ampicillin, at 37°C, 
225 rpm for 12-16 hrs. The cells were then transferred into culture flasks containing 1 L LB and 
50 𝜇g/mL ampicillin and let grow at 37°C, 225 rpm. At an optical density (OD) of 0.5 (600 nm), 
0.2 mM IPTG was added and the cells let express for 4 hrs at 37°C, 225 rpm, then harvested at 
5,000 rpm for 10 min and frozen at -80°C.  
 
MBP-TrnB, MBP-TrnB/KR5/KR10 and MBP-TrnB-CBD purification 
The cell pellets were resuspended in Buffer C (20 mM Tris/HCl, 0.2 M NaCl, 1 mM EDTA, 
1 mM DTT, pH 7.4), transferred into a glass beaker, lysed and centrifuged using the same 
procedure described for TrnC. MBP-TrnB was purified by FPLC, with an amylose resin affinity 
column (NEB). The column was equilibrated at 5 mL/min with Buffer C, the lysate containing 
MBP-TrnB was then loaded at 2 mL/min and the column washed with Buffer C at 2 mL/min until 
the absorbance was stable at ~0.2 AU. The protein was eluted with Buffer D (Buffer C + 10 mM 
maltose) at 5 mL/min and the collected fractions concentrated using Amicon Centrifuge Filters 
30k MWCO (Millipore). MBP-TrnB desalted through a P2 size exclusion resin (Bio-RAD) 
(elution buffer: 50 mM Tris/HCl, pH 8.0), concentrated again, identified by SDS-PAGE using 
PageRuler Unstained Protein Ladder (Thermo) and stored at -80°C. 
 
Cleavage of CBD fusion 
Cleavage of the chitin binding domain was carried out following a modified protocol from 
the one provided by the manufacturer (NEB)41. After the initial amylose purification and desalting 
steps, the protein solution was adjusted to 20 mM Tris/HCl (pH 8.5), 0.5 M NaCl, 1mM EDTA. 
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The cleavage reaction was initiated in solution adding 40 mM DTT and the mixture was incubated 
at 4°C overnight. A chitin resin column was equilibrated with the same buffer and the cleavage 
mixture was loaded. The flow-through was collected and CBD was eluted with 0.3 M sodium 
hydroxide. The two fractions were evaluated by SDS-PAGE. The resulting protein MBP-TrnB 
was dialyzed overnight in 50 mM Tris/HCl (pH 8.0). 
 
Cleavage of MBP fusion 
Tobacco Etch Virus protease gene was purchased in a pRK793 vector, transformed in 
BL21 Star (DE3), expressed and purified using the procedure described for TrnD. TEV protease 
was divided in small aliquots and stored at -80°C until further use. Cleavage of the MBP portion 
by TEV protease was carried out following a standard procedure42. The protein solution was 
adjusted to 50 mM Tris/HCl (pH 8.0), 0.5 mM EDTA, 1 mM DTT. TEV protease was added in a 
ratio of 1:100 protease/target protein and the cleavage carried out at 4°C overnight. A Ni-NTA 
resin column was equilibrated with the cleavage buffer. The crude mixture was then loaded onto 
the column and the flow-through collected in fractions. The cleavage buffer with the addition of 
200 mM imidazole was used to elute TEV and MBP bound to the column. The flow-through 
fractions and the final elution were concentrated using 3k and 10k MWCO Amicon spin filters 
respectively, and analyzed by SDS-PAGE and HPLC-MS. The analysis was carried out in the 
same LC-QQQ system described for the SAM cleavage assays. Chromatography was performed 
on an Eclipse XDB C18 column (Agilent), flow 0.7 mL/min, with a linear gradient 20-80% 
acetonitrile in H2O (with 0.1% formic acid. The UV trace was recorded at 210 nm. 
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SUMO-TrnA/TrnB cloning 
Two micrograms of pETHSUL vector were treated with 4 units of BseRI and 4 units of 
FastAP thermosensitive alkaline phosphatase (Thermo) in a 50 𝜇L reaction tube, with CutSmart 
buffer (NEB). The mixture was incubated at 37°C for 15 minutes, then placed on ice. Since the 
restriction digest was not completed, the linearized plasmid was purified by agarose gel 
electrophoresis and Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare). Using 
a thermal cycler, 0.1 pmol of the eluted DNA were incubated for 25 minutes at 22°C with 2.5 units 
of T4 DNA polymerase, in the presence of 2.5 mM dCTP and 1 𝜇g of BSA, in a total volume of 
10 𝜇L, followed by inactivation at 75°C for 20 minutes. The product was either kept at 10°C and 
used within a short time, or stored at -20°C until further use. 
The genes encoding the precursor peptides TrnA and TrnB from Bacillus thuringiensis were 
supplied by Genscript in a pUC57 vector. The codons were optimized for recombinant expression 
in Escherichia coli. Primers were purchased by Integrated DNA Technologies. The genes were 
amplified by PCR, using the pUC57 vector as template, with Takara PrimeSTAR Max DNA 
Polymerase (Takara Bio) (30 cycles, annealing at 55°C for 5 sec). 
In 10 𝜇L, 0.2 pmol of TrnA(B) PCR products were treated with T4 DNA polymerase following 
the same procedure described for pETHSUL, but substituting dCTP with 2.5 mM dGTP. 
The treated inserts and vector were combined in different ratios in the smallest volume possible 
and incubated at room temperature for 10 minutes, before addition of 15 mM EDTA and further 5 
min incubation at r.t. The mixture was directly transformed into E. cloni competent cells (Lucigen) 
following the manufacturer’s protocol. The circular vector alone was used as a positive control 
and linearized and treated with T4 DNA polymerase pETHSUL as negative control. 
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The cells were grown in LB medium with 50 𝜇g/mL ampicillin at 37°C for 14 hrs and the plasmid 
purified using Monarch Plasmid Miniprep Kit (NEB). In order to proceed with protein expression, 
pETHSUL-TrnA plasmid was transformed following the heat shock protocol into E. coli BL21 
Star (DE3) cells and pETHSUL-TrnB in BL21(DE3)pLysS (no particular reason for this choice, 
just comparison of the expression levels). 
 
Expression and purification of SUMO-TrnA/TrnB 
BL21 cells were grown in LB medium containing 50 𝜇g/mL ampicillin, at 37°C, 225 rpm 
for 12-16 hrs. They were then transferred into culture flasks and grown in 1 L LB and 50 𝜇g/mL 
ampicillin at 37°C, 225 rpm, until  an OD600 of 0.5. IPTG was added at a final concentration of 0.2 
mM and the cells let express for 3 hrs at the same temperature, then harvested at 5,000 rpm for 10 
min and frozen at -80°C. SUMO-TrnA(B) purification was carried out following the procedure 
described for TrnD, with the only difference in the P2 size-exclusion column elution buffer, being 
50 mM Tris/HCl (pH 8.0) in this case. The spin-filter concentrators used were 10k MWCO. The 
proteins were concentrated down to ~4 mg/mL (measured by Bradford assay), because if 
concentrated further they started to form a white precipitate. 
 
Expression and purification of dtUD1 protease 
The plasmid pSUPER was kindly provided by Dr. P. Loll. This plasmid encodes a SUMO 
fusion of the dtUD1 that self-cleaves during expression in E. coli. Following Loll’s procedure43, 
pSUPER was transformed into E. coli BL21 Star (DE3) cells and 10 mL of LB containing 50 𝜇g/mL ampicillin and 25 𝜇g/mL chloramphenicol were inoculated with a single colony, and 
allowed to grow at 37°C, 225 rpm overnight. One milliliter of the preculture was used to inoculate 
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1 L of LB in culture flasks containing the same antibiotics. The cultures were grown until they 
reached an OD600 = 0.5 and IPTG was added to a final concentration on 0.2 mM. The cells were 
let expressing for 3-4 hrs, harvested and frozen at -80°C. The pellet was resuspended in 50 mM 
sodium phosphate (pH 8.0), 250 mM NaCl, 25 mM imidazole, 10% w/v glycerol, 5 mM β-
mercaptoethanol and 10 mM MgCl2. A protease inhibitor cocktail tablet (Thermo) was also added. 
The cells were lysed using ultra-sonication and the insoluble cell debris centrifuged at 20,000 rpm, 
1 hr. A Ni-NTA resin column was equilibrated with the resuspension buffer. The soluble cell lysate 
was loaded onto the column and washed with the same buffer at 2 mL/min, until absorbance was 
stable at ~0.2. The protein was eluted at 5 mL/min in 50 mM sodium phosphate (pH 8.0), 250 mM 
NaCl, 300 mM imidazole, concentrated down with 10k MWCO centrifuge filters (Amicon) and 
dialyzed against 20 mM Tris/HCl (pH 8.0), 150 mM NaCl, 20%  (w/v) glycerol, 1 mM EDTA and 
5 mM DTT at 4°C, overnight, using SnakeSkin dialysis tubing (Thermo). The protein was diluted 
to a concentration of 0.25 mg/mL in the storage buffer (20 mM Tris/HCl (pH 8.0), 150 mM NaCl, 
50%  (w/v) glycerol, 1 mM EDTA and 5 mM DTT, divided in small aliquots and frozen at -80°C 
for later use. Dr. P. Loll claims that dtUD1 can be stored in these conditions at -20°C or -80°C for 
6 months with no apparent loss of activity. 
 
Cleavage of SUMO fusion protein 
The SUMO fusion protein was cleaved using dtUD1 protease in a 1:200 protease/protein 
ratio. In order to optimize the cleavage conditions, to a 20 mL solution of ~4 mg/mL protein in 50 
mM Tris/HCl (pH 8.0), NaCl, EDTA and DTT were added to a final concentration of 150 mM, 1 
mM and 2 mM respectively. At r.t., 400 𝜇g of dtUD1 were added to the protein solution and 
incubated for 1 hr. The solution was loaded at 5 mg/mL onto a Ni-NTA column, previously 
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equilibrated with the same buffer, and the flow-through was collected. When the absorbance was 
stable around 0.2 A, the buffer was switched to Buffer B and a second peak was collected in a  
separate fraction. The fractions were analyzed by SDS-PAGE and UPLC/Q-ToF MS. The 
supernatant was filtered through a 0.22 𝜇m membrane and an aliquot injected onto an Agilent 
Zorbax C-18 column (4.6 mm X 250 mm) pre-equilibrated in 20% ACN in H2O, 0.1% (v/v) formic 
acid.  The peptide was eluted in a linear gradient 20-100% ACN over 8 min, 1 mL/min flow. The 
Q-ToF was operated in positive mode. For the MS/MS analysis, the peak corresponding to the +3 
charge state was fragmented (for both TrnA and TrnB), with low collision energy.   
 
In vitro TrnC and TrnD assays 
The activity of TrnC and TrnD was tested in vitro using TrnA as substrate, since its 
purification led to a cleaner mixture compared to TrnB. Similarly to the SAM cleavage assays 
described, all the reactions were carried out under anaerobic conditions in an inert atmosphere 
glovebox. All the stock solutions were brought into the box and let incubate with nitrogen for about 
1 hr. The final volume for each assay was 100 𝜇L in 50 mM Tris/HCl, 0.1 M NaCl (pH 8.0) buffer. 
In order to reconstitute further the iron-sulfur clusters, 12 𝜇M of TrnC/25 𝜇M TrnD were incubated 
at r.t. for 15 min with 5 mM DTT, 200 𝜇M ammonium iron(III) citrate and 200 𝜇M sodium sulfide. 
TrnA was added to a final concentration of ~100 𝜇M (estimated, from dtUD1 cleavage step), 
followed by addition of 500 𝜇M SAM and 15 min incubation at rt. To initiate the reaction, 1 mM 
sodium dithionite was added and the mixture incubated at r.t. for 3-4 hrs. Controls with no SAM, 
or no peptide, or no reducing system were also carried out. The proteins were then denatured with 
20% ethanol, the reaction tubes placed on ice for 15-20 min and the precipitate spun down in a 
microcentrifuge at 14,000 rpm for 10 min. The supernatant was analyzed by mass spectrometry. 
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Co-expression of TrnA + TrnC/D and TrnA purification 
pETHSUL-TrnA was co-transformed in BL21 Star (DE3) E. coli cells with pET-28a(+)-
TrnC and pET-28a(+)-TrnD (separately), in order to test if any modifications would occur in vivo. 
The cells were plated in LB agar plates containing 50 𝜇g/mL ampicillin and 25 𝜇g/mL kanamycin. 
The same experiment was repeated with pETHSUL-TrnB, but no colonies were observed on the 
plates. A colony from each plate (TrnA+C and TrnA+D) was used to inoculate two 10 mL LB 
cultures containing the same antibiotics. Expression was carried out as described for TrnC(D). 
Purification followed the procedure described for SUMO-TrnA/B, with Ni-affinity 
chromatography and desalting size-exclusion. As expected, TrnC precipitated as soon as exposed 
to oxygen, but without affecting the purpose of this study. Concentration of SUMO-TrnA was 
indirectly estimated: using a Bradford assay TrnD + SUMO-TrnA concentration was determined. 
TrnD concentration was estimated from the 410 nm absorbance of its [4Fe-4S] cluster (ε = 16,000 
M-1 cm-1) (not present in SUMO-TrnA) and subtracted to TrnD + SUMO-TrnA concentration, to 
obtain an estimation of SUMO-TrnA. Cleavage of the SUMO fusion was carried out following the 
procedure described for SUMO-TrnA(B). SUMO and TrnD were retained by Ni-resin and TrnA 
was collected in the flow through and concentrated. All the steps described were analyzed by SDS-
PAGE. TrnA final elution was analyzed by HPLC-MS. 
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Results and Discussion 
 
TrnC and TrnD 
The genes trnC and trnD, which code for the presumed sactisynthases, were cloned into 
pET-28a(+) plasmids, in order to have a different antibiotic resistance from the two peptides, for 
future co-transformation experiments. They also included a N-terminal His6-tag, with a thrombin 
cleavage site between the tag and the protein. Temperature and incubation time for protein 
expression in BL21 Star (DE3) E. coli were optimized for both enzymes to 5-6 hrs at 25°C, with 
20 mg/L yield for TrnD and 6 mg/L for TrnC. TrnC in unstable in aerobic conditions, as reported 
for several radical SAM enzymes. This complication is typically attributed to protein unfolding 
and precipitation as a consequence of exposure to oxygen, responsible for iron oxidation and 
subsequent degradation of the iron-sulfur clusters44. TrnD did not show the same behavior and it 
was stable throughout purification. Nonetheless, TrnD has to be stored in relatively high 
concentration of thiol-reducing agents (such as β-ME) and glycerol, otherwise, the solution quickly 
becomes cloudy and the protein precipitates if subjected to freeze-thaw. Noticeably, TrnC and 
TrnD were found to be very stable over several hours at room temperature after reconstitution, if 
kept under strictly anaerobic conditions (inert atmosphere glovebox).  
After overnight iron-sulfur cluster reconstitution in a buffer containing Fe, S and DTT, and 
subsequent size-exclusion chromatography to remove any excess salts, the Fe and S content was 
determined. The analysis resulted in 4.3 ± 0.2 equiv. of S and 5.1 ± 0.3 equiv. of Fe for TrnC, 3.2 
± 0.5 eq. S and 4.5 ± 0.2 eq. Fe for TrnD. These results are in accordance with some sactisynthases 
previously described and they indicate the presence of at least one [4Fe-4S] cluster for each 
enzyme. This cluster probably corresponds to the radical SAM Fe-S cluster (and not a possible 
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auxiliary one), because it is likely to be the most readily reconstituted. Moreover, the proteins 
would probably unfold and precipitate if the main cluster is not formed. At this stage, the presence 
of other Fe-S clusters cannot be excluded, because reconstitution of the clusters in vitro is not 
always possible. Auxiliary clusters might be present in vivo and degrade during purification. 
Degradation of these clusters would likely not cause the proteins to unfold, as shown in previous 
studies23. Since TrnC and TrnD sequence alignment results in several sequence identities with 
sactisynthases that contain auxiliary clusters, site-directed mutagenesis studies of the SAM clusters 
and SPASM domain cysteine residues are required to further investigate this matter. Mutation od 
different cysteine residues would show if the cluster which is being reconstituted is the radical 
SAM cluster or the auxiliary one. 
A qualitative analysis of the Fe-S cluster(s) is shown in Fig. 21, TrnC and TrnD 200-700 nm 
absorbance profile. The characteristic absorbance trace for [4Fe-4S] cluster proteins has its 
maximum peak at 410 nm (ε = 16,000 M-1 cm-1)45. Upon addition of sodium dithionite, this peak 
is shown to be partially or significantly reduced for other sactisynthases12,21, with loss of the 
usually brown color of the solution. TrnC and TrnD Fe-S cluster(s) were surprisingly very stable 
to anaerobic reduction with sodium dithionite, even after long periods of incubation (hours to 
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Figure 21. TrnC and rnD UV-vis profile. In blue, TrnC Fe-S cluster(s) partial reduction by sodium dithionite. 
TrnD did not show any change in the spectrum upon addition of DTN.  
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overnight). The absorbance peak at 410 nm was reduced by only ~13% in intensity for TrnC, 
similar to previously reported reductions of [4Fe-4S]2+ to [4Fe-4S]1+ for biotin synthase46 and 
YydG36. However, the data is not totally comparable, because an increase in absorbance at 330 nm 
corresponding to sodium dithionite oxidation is usually observed. In these examples, absorbance 
at 410 nm also increases again upon oxygen exposure. This is in contrast with the hypothesis that 
the SAM [4Fe-4S]2+ cluster is the one to be reconstituted, because it would also readily reduce 
after addition of DTN, unless particularly stable or protected in the active site. As already 
mentioned, further site-directed mutagenesis studies of the cysteines would be important for a 
better understanding of these spectra. No significant change was observed for TrnD (not shown). 
In order to understand what reducing system works best for both proteins, assays containing the 
protein, SAM and different reducing systems were run under anaerobic conditions, analyzed by 
HPLC to identify SAM background cleavage and compared to 5’-deoxyadenosine standards (Fig. 
22). When incubated with sodium dithionite or titanium(III) citrate, TrnC was able to consume 
some of the SAM and produce detectable quantities of 5’-deoxyadenosine; no SAM cleavage was 
observed if TrnC was treated with the NADPH/Fld/FNR system, shown to reduce other radical 
SAM enzymes. TrnD did not produce 5’-dAH with any of the reducing systems. All the 
sactisynthases previously reported have shown the ability to cleave SAM and produce 5’-dAH 
upon DTN reduction, even without any substrate bound. Therefore, since TrnD also does not show 
any change in the Fe-S cluster UV-vis spectrum analysis when sodium dithionite is added, the 
SAM [4Fe-4S]2+ cluster is either not reacting or not being reconstituted. In the second case, an 
auxiliary [4Fe-4S]2+ cluster could be forming and showing in the UV-vis spectrum, but could not 
react with SAM. 
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Figure 22. A. SAM cleavage assay. Total Ion Chromatogram (TIC) of SAM cleavage assays with TrnC; 
5’-deoxyadenosine elutes at 11.0 min. In red, controls where either TrnC or S-adenosylmethionine were 
not added. For the controls, no 5’-dAH is observed. 
 
 
In Fig. 23, TrnC and TrnD sequence alignment with the main members of the sactisynthase 
family is shown. As expected, the CXXXCXXC motif is perfectly aligned and conserved among 
all enzymes. Noticeably, three cysteines in the SPASM domain are 100% conserved even if at 
different distance from each other. As discussed previously, these Cys have been shown to 
coordinate an auxiliary Fe-S cluster for other sactisynthases and, since they are conserved in TrnC 
and TrnD, the presence of a secondary cluster is expected. TrnC and most other sactisynthases also 
contain a third set of three cysteines in the SPASM domain, whereas TrnD does not. TrnC shows 
very good sequence alignment with Tte1186, especially near the C-terminus where this enzyme 
has been reported to coordinate two auxiliary clusters, with strong evidences supported by 
mutation of several different Cys. Overall, TrnD is likely to coordinate at least one auxiliary Fe-S 
cluster and TrnC two. These clusters might be lost during protein purification and the proteins 
might not be (or only partially) reconstituting them in vitro. But, since TrnC was shown to cleave 
SAM and form 5’-dAH under reducing conditions, the [4Fe-4S]2+ cluster coordinated to the 
CXXXCXXC motif is likely to be undergoing reduction, despite the ambiguity of the UV-vis 
spectral data. 
 
A 
5’-dAH 
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Figure 22. B. 5’-deoxyadenosine extracted-ion chromatogram. [M+H]+ = 252.1 is the major peak and 
fragmentation to adenine (136.1) the minor peak, as expected. 253.1, corresponding to 5’-dAH 13C 
isotopes is also detected. C. TIC of SAM cleavage assay with TrnD. No 5’-dAH is detected with any of the 
reducing systems used. 
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Figure 23. TrnC and TrnD MUSCLE sequence alignment. MUSCLE sequence alignment including TrnC, 
TrnD and most of the sactisynthases described. The blue arrows indicate the radical SAM domain, whereas the 
red arrows indicate cysteine residues in the SPASM domain, possibly involved in coordinating one or two 
auxiliary clusters. Red = 100% conserved, blue = 75%, gray = 50%. 
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TrnA and TrnB 
Expression and purification of TrnA and TrnB was very challenging due to their poor 
solubility in water and small size. Both peptides are comprised of a majority of hydrophobic 
residues, with only a few charged amino acids concentrated near the N-terminus. The natural 
product thuricin CD reported by Rea et al.27 was isolated from B. thuringiensis cell pellet by 
extraction in 70% aqueous isopropanol (acidified to pH 2.0), relatively harsh conditions which 
indicate an issue in solubility. The first attempt in expression and purification of thuricin CD 
precursors was to clone TrnA(B) into a pET plasmid, and transform and express in E. coli. 
Following the procedure just described, the cell pellets were extracted in 70% isopropanol (pH 
2.0), but none of the peptides were detected by further analyses. The reasons for this are probably 
the following: Thuricin CD is likely to be more soluble than its linear precursors TrnA and TrnB, 
due to its more compact partial secondary structure imparted by the thioether crosslinks and shorter 
length (~20 residues shorter); expression in E. coli might not be optimal compared to B. 
thuringiensis; lastly, the linear precursors are more likely to be subjected to protease degradation 
during expression. In regard to Subtilosin A, Tte1186a and CteA, the precursor peptides were 
simply His-tagged and purified by Ni-affinity chromatography in aqueous conditions. However, 
addition of a N-terminal His6-tag to TrnA and TrnB and purification through Ni-affinity 
chromatography, did not result in any detectable peptide. 
 
MBP-TrnB 
The first positive results in TrnA(B) isolation were found with the introduction of a fusion 
protein at the N-terminus of the peptide. Initial attempts were focused on TrnB, because its amino 
acid sequence contains a tryptophan residue, making this peptide more UV-active compared to 
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TrnA, which does not contain any residue with a chromophore. The plasmid selected was pMAL-
c2x, expressing a maltose-binding protein (MBP), which may also improve the purification step, 
since it requires the use of amylose-affinity chromatography, shown to result in a lower non-
specific protein background binding in some cases, compared to Ni-affinity47. Using this type of 
resin also avoids high imidazole concentrations in the elution buffer, which would require 
subsequent purification steps. Low concentrations of maltose, compatible with further 
experiments, are sufficient to elute the protein. Therefore, TrnB was cloned into pMAL-c2x at the 
C-terminus of MBP. From the commercial vector, the cleavage sequence between MBP and TrnB 
was mutated to a Tobacco Etch Virus (TEV) protease cleavage site, with the addition of an extra 
serine at the N-terminus of the target peptide. MBP and TEV protease were both His6-tagged at 
the N-terminus, in order to be purified together after the final cleavage step. As shown in the SDS-
PAGE in Fig. 24, the protein construct was successfully purified, but during expression, or lysis 
and centrifugation, a large fraction of MBP-TrnB (~47,000 kDa) was degraded to MBP only 
(~42,000 kDa) (lane 1). In fact, after TEV protease cleavage (lane 2), the MBP-TrnB band 
combines to the MBP band. An unknown contaminant below the 40 kDa marker is also detected. 
Proteolysis degradation is a common issue for small target 
proteins/peptides expressed with a fusion partner. TrnB is 
easily degraded in this case, because it is a short linear peptide 
protruding from a large globular protein with well-defined 
structure. Different expression time and temperatures did not 
make any significant difference. From the gel, the degradation 
issue seems to decrease the final purification yield 
approximately by half. Moreover, TrnB is only 10% by mass 
∼60∼70∼85∼100∼50∼40
∼120
∼30
kDa∼150∼200 1 2
Figure 24. MBP-TrnB SDS-PAGE. 
Lane 1: full length MBP-TrnB; 
lane 2: after TEV protease cleavage. 
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of the total fusion MBP-TrnB protein. Therefore, for example, with ~100 mg/L yield after 
purification of MBP-TrnB, and half corresponding to the truncated protein, total TrnB after TEV 
protease cleavage would be only ~5 mg/L. TEV protease activity is also not always optimal with 
such globular proteins, and it requires further Ni-affinity chromatography purification, decreasing 
the final yield even more. The amount of TrnB isolated was simply too low to carry out further 
experiments and a different strategy was adopted.  
 
MBP-TrnB-CBD 
In order to prevent proteolytic degradation, a second double fusion protein system was 
engineered, with the idea of having the peptide between two well expressing proteins. For this 
purpose, an intein-tag containing a chitin-binding domain (CBD) was attached to TrnB C-
terminus. This type of fusion protein is easily cleavable upon addition of high DTT concentrations 
(40 mM or higher) and can be purified 
by chitin-affinity chromatography. 
Although this choice adds a second 
cleavage and purification step, 
degradation of TrnB from the C-
terminus would be completely avoided 
(Fig. 25). The manufacturer suggests 
running the CBD cleavage on a chitin-
resin column, but yields were much 
higher for cleavage in solution for our construct. However, after the final TEV protease cleavage, 
the peptide yield was still very low, and it was not possible to recover TrnB from the final Nickel 
Target peptideMBP TEV Intein CBD
40 mM DTT,
Chitin resin
Target peptideMBP TEV
CBD
TEV protease,
Ni-NTA resin
MBP
Target peptide
Figure 25. MBP-TrnB-CBD purification scheme. 
TrnB is eluted in the final Ni-column flow-through. 
“TEV” in the figure indicates TEV protease 
recognition sequence. 
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resin purification step. As reported for other short hydrophobic peptides expressed with a fusion 
partner, HPLC purification was attempted. The UV trace resulted in several peaks that were 
collected separately, concentrated and analyzed by mass spectrometry. The peptide was identified, 
but the thiolates of all three cysteines required for activity were irreversibly oxidized to sulfonic 
acid, making TrnB soluble in water, but the thioether crosslink formation reaction impossible to 
study. The peaks shown in Fig. 26 correspond to the [M+3]3+ (1712.60), [M+4]4+ (1284.20) and 
[M+6]6+ (856.70) charge states of TrnB plus nine oxygen atoms, three for each cysteine. This 
oxidation probably occurred during the overnight cleavage of CBD step with DTT, during which 
oxygen oxidized the cysteines, and such high DTT concentration, probably containing some 
oxidized DTT, also acted as a catalyst for cysteine oxidation. A new approach that avoids high 
concentrations of DTT was needed, and CBD as fusion protein was not further considered a viable 
option. 
 
 
 
TrnB, all Cys 
oxidized: 
[M+3]3+ (1712.60), 
[M+4]4+ (1284.20),           
[M+6]+6 (856.70) 
Figure 26. TrnB Cys oxidation.  
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MBP-KR5/10-TrnB 
Berteau et al. successfully purified a truncated version of polytheonamide A at the N-
terminus48, a peptide with a short sequence of hydrophobic residues, after the addition of five 
lysine residues at the N-terminus. Applying a similar strategy, TrnB solubility was increased by 
the addition of five (MBP-KR5-TrnB) and ten (MBP-KR10-TrnB) cationic residues (a 
combination of lysine and arginine) at the amino end. Since all TrnC/D modifications form near 
the C-terminus, addition of these residues was thought to only minimally affect TrnB reactivity. 
Following the procedure described for MBP-TrnB, the expression levels were drastically low and 
recovery of only ≤ 1 mg/L of the fusion protein was possible, still contaminated with the truncated 
version (MBP). Again, after the TEV cleavage, it was impossible to isolate the peptide with Ni-
affinity chromatography. TrnB was also not detectable by MS from the crude cleavage mixture, 
probably due to its little amount compared to MBP and TEV proteins, and hard to separate under 
their broad peaks. However, for the first time it was possible to reproducibly identify the peptide 
by 8-16% acrylamide gradient SDS-PAGE, using a modified Coomassie Blue gel dye solution 
Figure 27. SDS-PAGE, MBP-KR5/10-TrnB. 
Lane 1 and 2: TEV protease; 
lane 3: purified MBP-KR5/10-TrnB; 
lane 4, 5, 6: different amounts of MBP-
KR5/10-TrnB after TEV protease cleavage. 
The peptide is the faint band slightly above the 
10 kDa band of the ladder. 
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(AquaStain, Bulldog Bio) (Fig. 27). Due to the inaccuracy of SDS-PAGE in analyzing small 
molecules, the peptide runs with the smallest band of the ladder (~10 kDa) and seems to be larger 
than it should. Aprotinin (~6kDa) was used as a standard and KR5/KR10-TrnB (~5.5 kDa) was 
perfectly comparable to it. Unfortunately, due to the very low expression and purification yields, 
it was not possible to carry out further experiments with these compounds, and a new strategy was 
adopted. Additionally, the number of positive charges, be it five or ten Arg/Lys residues, did not 
make a significant difference overall. 
 
SUMO-TrnA/TrnB 
A different approach was taken, exchanging the N-terminal fusion partner MBP for a 
smaller protein with more optimal final protease cleavage and purification steps, following similar 
successful sactipeptides purification approaches reported18, 21. Marahiel et al. use thioredoxin 
(TXN) as a fusion protein, which is approximately 11.7 kDa and a TEV or HRV-3C protease 
cleavage site. TEV and HRV-3C 
perform sequence specific proteolysis 
and require subsequent HPLC 
purification of the peptide. Dr. P. Loll 
kindly donated to us plasmids encoding 
Small Ubiquitin-like Modifier (SUMO) 
fusion protein, a small protein (~12 
kDa) that can be cleaved by a highly 
specific protease, which recognizes the 
tertiary structure of SUMO rather than 
Figure 28. pETHSUL vector. The genes trnA and trnB were 
inserted in frame with the SUMO fusion protein, using LIC 
(BseRI restriction digest site). 
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an amino acid sequence49.  The plasmid encoding this protein was also donated to us, and both 
SUMO and dtUD1 (dtUD1, doubly-tagged ubiquitin domain 1 protease) contained a His6-tag, 
convenient for purification. The E. coli codon-optimized genes trnA and trnB were cloned into the 
vector through ligation independent cloning (LIC), at the SUMO C-terminus, following a modified 
version of the procedure published by the Loll group43. The plasmid selected was pETHSUL (Fig. 
28), where pET is the parent vector, H stands for hexa-histidine tag and SUL for SUMO LIC. The 
LIC process (outlined in Fig. 29) was chosen to avoid restriction enzyme/T4 ligase traditional 
methods, which are time consuming and often only few genes are successfully inserted, requiring 
Figure 29. Ligation independent cloning workflow for pETHSUL-TrnA(B). 
 
R-primer 5’- GAGGAGAGTTTAGACTTACAGGAAATAAGATGCCGCCGCAA -3'
pETHSUL-TrnA
F-primer 5'- AGATTGGTGGCATGGAAGTCATGAACAATGCACTGATTACC -3'
R-primer 5'- GAGGAGAGTTTAGACTTAACCCAGCGTAAACGCGGTG -3'
pETHSUL-TrnB
F-primer 5'- AGATTGGTGGCATGGAAGTCCTGAACAAACAGAACGTG -3'
Table 1. pETHSUL-TrnA(B) cloning primers.  
 
GAACAGATTGGTGGCGTCTAAACTCTCCTCGAGAAGCTT
CTTGTCTAACCACCGCAGATTTGAGAGGAGCTCTTCGAA
GAACAGATTGGTGGCG                    TCTAAACTCTCCTCGAGAAGCTT
CTTGTCTAACCACC                    GCAGATTTGAGAGGAGCTCTTCGAA
GAAC                                                      TCTAAACTCTCCTCGAGAAGCTT
CTTGTCTAACCACC                                                                  CTCTTCGAA
BseRI 
+
AP
T4 DNA pol
+
dCTP
T4 DNA pol
+
dGTP
AGATTGGTGGCnnn . . . . . nnnGTCTAAACTCTCCTC
TCTAACCACCGnnn . . . . . nnCAGATTTGAGAGGAG
AGATTGGTGGCnnn . . . . . nnnG
                           Gnnn . . . . .  nnCAGATTTGAGAGGAG
GAAC                                                        TCTAAACTCTCCTCGAGAAGCTT
CTTGTCTAACCACC                                                                  CTCTTCGAA
AGATTGGTGGCnnn . . . . . nnnG
                           Gnnn . . . . . nnCAGATTTGAGAGGAG
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extra steps, such as colony PCR. The vector is linearized 
using the restriction enzyme BseRI, then treated with T4 
DNA polymerase, which, in the presence of dCTP only, 
generates 10- and 14-base single strand overhangs 
through its 3’ → 5’ exonuclease activity. The target gene 
is amplified using primers containing a region 
complementary to this overhang and the nucleotide 
sequence required for annealing to the template. The 
primers used are shown in Table 1. The reverse primers 
also include a termination sequence, because the final 
peptide would contain an extra valine residue at the C-
terminus otherwise. PCR products were treated with T4 
DNA polymerase in the presence of dGTP, to generate 
the complementary single stranded overhangs. The 
treated vector and insert were mixed together and, after 
short incubation, simply transformed into E. coli. 
competent cells, that naturally repair the four resulting 
nicks. Competent cells prepared with calcium chloride 
from BL21 or DH5α cells grown from glycerol stocks would not always result in successful 
transformation. Therefore, commercial competent cell strains with higher transformation 
efficiency, such as Stellar (Takara) or Ecloni 10G (Lucigen) were utilized instead. Even with these 
strains, the transformation yielded only one to ten colonies per LB agar plate. pETHSUL restriction 
digest with BseRI was not complete (Fig. 30), therefore, the linearized vector (lane 2, 5677 bp) 
3.0
4.0
5.0
6.0
2.0
1.5
1.0
8.0
10.0
Kilobases 1 
 
2 
 
Figure 30. pETHSUL BseRI 
restriction digest. 
Lane 1: undigested vector. 
Lane 2: BseRI digest. 
 
3.0
4.0
5.0
6.0
2.0
1.5
1.2
1.0
0.5
0.4
0.3
0.2
Kilobases
Figure 31. TrnA and TrnB PCR 
products. Generated using primers 
for LIC. TrnB   band (right lane, ~0.2 
kb) was purified from the agarose.  
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was purified using an agarose gel purification kit (GE Healthcare). This step was necessary 
because transformation would be much more selective for the contaminating circular plasmid, 
compared to the new construct formed by LIC. TrnA and TrnB PCR products from the pUC57 
plasmid, using the primers indicated in Table 1 are shown in Fig. 31. TrnB (on the right) was gel 
purified as well. DNA sequencing (using the same set of primers) confirmed insertion of the genes. 
Using this construct, the SUMO-TrnA/TrnB protein expression levels increased to ~120 mg/L, 
measured by Bradford protein assay. Noticeably, the constructs are slow in fully reacting with the 
Bradford dye (4-5 minutes). Since the SUMO protein is much smaller than MBP, the peptide 
corresponds to ~30% of the total mass, underscoring the increased yield in this system compared 
to the MBP-TrnB construct. The SUMO protease dtUD1 plasmid was transformed into BL21 Star 
(DE3) E. coli cells, expressed and purified following Loll et al. procedure, and finally stored in 
low concentrations (0.25 mg/L), in a high DTT (10 mM) and glycerol (20%) content buffer. A 
ratio of 1:200 dtUD1/SUMO-TrnA(B) was sufficient to completely cleave the SUMO fusion 
protein in one hour, at room temperature. Overall, this step was also an improvement in time 
consumption and cleavage efficiency in particular. The cleavage mixture was loaded onto a Ni-
affinity resin column by FPLC, and collection of the flow-through after dtUD1 cleavage afforded 
a broad absorbance peak for both peptides. Noticeably, TrnA(B) elution fraction resulted in a pale-
yellow solution, perhaps due to unspecific Ni binding, but the reasons for this color have not being 
explored further. TrnA and TrnB were identified by SDS-PAGE (Fig. 32), showing a band shift 
corresponding to the loss of ~5,000 Da between the SUMO construct before and after cleavage. 
The Ni-resin elution band, after dtUD1 cleavage, also run as far as the SUMO-only control, 
purified after expression of the pETHSUL vector. PAGE shows how some proteolysis during 
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expression might be occurring with this construct, as the SUMO-TrnA(B) bands are broad and 
seem to be almost two separate bands. But the reference SUMO-only band is also very broad, 
therefore it could just be a matter of amount of protein loaded.  
 
TrnA and TrnB MS analysis 
The Ni-resin flow-through elution fractions containing TrnA and TrnB after final dtUD1 
cleavage were analyzed by HPLC-MS. The spectrum for each peptide resulted in a complex 
mixture of several truncated peptides, losing fragments of different lengths from the C-terminus. 
The main peaks are summarized in Fig. 33 (TrnA) and Fig. 34 (TrnB). The full-length peptides 
are mainly present as [M+3H]3+, but they are in considerably low amount compared to the 
truncated peptides. MS/MS analysis was carried out targeting the [M+3H]3+ for fragmentation. 
Most of the b and y fragments were successfully recognized, as shown in Fig. 35 (TrnA) and Fig. 
36 (TrnB) and summarized in Table 2 and 3 respectively. The reasons for degradation of the full-
length peptide have not been explored thoroughly, but from the elongated shape of the bands on 
the polyacrylamide gel, the assumption can be made was that this degradation occurs via 
endogenous proteases during protein expression or cell lysis. This phenomenon is still observed at 
different time and temperature variation during expression, and the addition of different protease 
Figure 32. SDS-PAGE, SUMO-TrnA(B).  
Lane 1 SUMO-TrnA lysate; 
lane 2 SUMO-TrnB lysate 
lane 3, 4: Ni-resin flow-through; 
lane 5, 6, 7: Ni-resin elution; 
lane 8: SUMO no fusion (control); 
lane 9: crude dtUD1 cleavage mixture; 
lane 10: last Ni-resin flow-through; 
lane 11: last Ni-resin elution (+ imidazole). 
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inhibitor does not seem to have any effect. The hypothesis that SUMO protease degrades the 
peptides by non-specific cleavage was considered, but since this protease shows >85% specificity 
in cleaving at the +1 position of SUMO C-terminus residue (unless it is a proline, which is not the 
case)49,50, it seems unlikely. Another hypothesis is spontaneous degradation. The peptides do not 
encounter any particularly harsh condition during the purification process, therefore this option 
does not seem valuable. Noticeably, the most abundant peak is for both TrnA and TrnB a truncation 
at the amino acid residue in the position right before the first cysteine. 
 
 
 
Fragment Time (min) Ion Predicted Observed Diff.
MEVMNNA 1.284 [M+H]+ 808.33283 808.3450 0.01217
MEVMNNALIT 1.690 [M+H]+ 1135.54864 1135.5518 0.00316
[M+H]2+ 568.27798 568.2797 0.00172
MEVMNNALITKVDEEIGGNAA 1.813 [M+H]2+ 1110.0378 1110.0429 0.0051
[M+H]3+ 740.36098 740.3637 0.00272
MEVMNNALITKVDEEIGGNAACVIGCIGSCVI 2.111 [M+H]2+ 1633.7836 1633.8143 0.0307
[M+H]3+ 1089.5248 1089.5466 0.0218
[M+H]4+ 817.39545 817.4186 0.02315
Full-lenght TrnA 2.376 [M+H]3+ 1552.7628 1552.7979 0.0351
MEVMNNALITKVDEEIGGNAACVIGCIGSCVISEGIGSLVGTAFTLG [M+H]4+ 1164.8239 1164.8492 0.0253
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Time (min)
MEVMNNA
MEVMNNALIT
MEVMNNALITKVDEEIGGNAA
MEVMNNALITKVDEEIGGNAACVIGCIGSCVI
TrnA
Figure 33. TrnA and TrnA degradation fragments identified by mass spectrometry.  
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Fragment Time (min) Ion Predicted Observed Diff.
MEVLNKQNVNIIPESEEVGGWVA 1.836 [M+H]2+ 1278.14419 1278.1410 -0.00319
[M+H]3+ 852.4319 852.4300 -0.0019
[M+H]4+ 639.57575 639.5762 0.00045
MEVLNKQNVNIIPESEEVGGWVACVG 1.968 [M+H]2+ 1407.69327 1407.6928 -0.00047
[M+H]3+ 938.79825 938.8008 0.00255
[M+H]4+ 704.35052 704.3553 0.00478
MEVLNKQNVNIIPESEEVGGWVACVGACGTVCL 2.232 [M+H]2+ 1731.33227 1731.3307 -0.00157
[M+H]3+ 1154.55729 1154.5586 0.00131
[M+H]4+ 866.1698 866.1711 0.0013
Full-lenght TrnB 2.332 [M+H]3+ 1664.1356 1664.1266 -0.009
MEVLNKQNVNIIPESEEVGGWVACVGACGTVCLASGGVGTEFAAASYFL [M+H]4+ 1248.34898 1248.3542 0.00522
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
Time (min)
MEVLNKQNVNIIPESEEVGGWVA
MEVLNKQNVNIIPESEEVGGWVACVG
MEVLNKQNVNIIPESEEVGGWVACVGACGTVCL
TrnB
Figure 34. TrnB and TrnB degradation fragments identified by mass spectrometry.  
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Fragment Predicted Observed Difference Intensity
y2+ 189.1234 189.1222 -0.0012 605.3951
y3+ 290.1711 290.1694 -0.0017 3428.9375
b3+ 360.1588 360.1595 0.0007 637.5079
y4+ 437.2395 437.2416 0.0021 1704.0376
y5+ 508.2766 508.2756 -0.0010 1933.2104
b153+ 573.2761 573.3014 0.0253 1013.2607
y6+ 609.3243 609.3291 0.0048 1094.2686
y7+ 666.3458 666.3425 -0.0033 7156.6802
y8+ 765.4142 765.4129 -0.0013 2013.0629
b152+ 859.4105 859.4025 -0.0079 736.5558
y9+ 878.4998 878.4903 -0.0095 677.8163
b162+ 915.9525 915.9524 -0.0001 1149.4702
b172+ 944.4632 944.4578 -0.0054 769.7198
y10+ 965.5303 965.5259 -0.0044 595.8893
b182+ 972.9739 972.9651 -0.0088 572.0882
y11+ 1022.5517 1022.5491 -0.0026 1814.2703
y333+ 1023.5083 1023.5552 0.0469 963.5298
b192+ 1029.9954 1029.9893 -0.0061 1101.2577
b202+ 1065.5140 1065.5057 -0.0083 954.2512
y343+ 1066.5225 1066.5121 -0.0104 986.3112
b212+ 1101.0325 1101.0349 0.0024 1736.5237
b10+ 1117.5381 1117.5321 -0.0060 830.4031
b222+ 1152.5371 1152.5280 -0.0091 502.0988
y13+ 1192.6573 1192.6441 -0.0132 454.7336
b232+ 1202.0713 1202.0630 -0.0083 2595.2898
b242+ 1258.6134 1258.6098 -0.0036 7149.2104
b252+ 1287.1241 1287.1248 0.0007 1413.6801
b12+ 1344.7015 1344.6930 -0.0085 417.5200
b423+ 1383.6731 1383.6638 -0.0093 458.7234
y15+ 1408.7319 1408.7285 -0.0034 1220.5385
y312+ 1413.6954 1413.6732 -0.0222 757.7804
b443+ 1456.3749 1456.3582 -0.0167 1045.6371
b13+ 1459.7289 1459.7061 -0.0228 440.2130
b453+ 1490.0575 1490.0510 -0.0065 1166.5560
y16+ 1521.8159 1521.7410 -0.0749 5347.0176
b463+ 1527.7521 1527.7555 0.0034 1265.0002
b473+ 1546.7593 1546.7506 -0.0087 3598.2422
y473+ 1552.7628 1552.7513 -0.0115 12072.1572
b14+ 1588.7710 1588.7504 -0.0206 535.0822
Table 2. List of TrnA MS/MS fragments. 
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Fragment Predicted Observed Difference Intensity
y22+ 140.08884 140.0669 -0.0219 300.1608
y2+ 279.17036 279.174 0.0036 969.529053
y3+ 442.23369 442.2307 -0.0030 610.377136
y4+ 529.25572 529.2584 0.0027 226.697586
y102+ 560.27153 560.2259 -0.0456 191.580307
y6+ 671.33995 671.3398 -0.0002 933.504822
y7+ 742.37706 742.3684 -0.0087 352.339111
y9+ 1018.48807 1018.4734 -0.0147 255.276672
b182+ 1034.02502 1034.0113 -0.0137 202.335251
b9+ 1056.55068 1056.5449 -0.0058 384.140747
y252+ 1176.056 1176.0806 0.0246 197.235397
y11+ 1176.55721 1176.563 0.0058 475.125
b212+ 1184.08614 1184.0779 -0.0082 251.568237
b222+ 1233.62035 1233.5951 -0.0252 359.301178
b11+ 1283.67768 1283.6706 -0.0071 309.139526
y13+ 1332.64709 1332.6421 -0.0050 253.495377
y14+ 1389.66855 1389.6633 -0.0053 253.198013
b12+ 1396.76174 1396.7627 0.0010 1508.04541
b262+ 1398.68844 1398.7573 0.0689 1363.41858
y15+ 1476.70058 1476.7032 0.0026 357.077484
b493+ 1658.12703 1658.1008 -0.0262 656.278015
y493+ 1664.13056 1664.1235 -0.0071 457.968933
b322+ 1665.78496 1665.8132 0.0282 875.294312
b15+ 1709.88912 1709.8425 -0.0466 185.520828
y372+ 1797.81496 1797.8045 -0.0105 482.84024
b442+ 2196.04442 2196.0631 0.0187 412.675201
Table 3. List of TrnB MS/MS fragments. 
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In the MS/MS spectrum, several fragments containing one to three cysteine residues for each 
peptide are observed. This will allow a detailed study of TrnC and TrnD in the thioether crosslinks 
formation once the C-terminal truncation issue is solved. As previously described for other 
sactipeptides, incubation with iodoacetamide or other cysteine alkylating agents will result in a 
large mass shift for free thiolates, and no difference in mass if the thioether crosslink is formed12,23.  
 
In vitro and in vivo attempted studies 
Since isolation of TrnA and TrnB by HPLC was not successful, a first attempt to observe 
thioether crosslink formation was carried out using the final Ni-resin elution (after SUMO protease 
cleavage), containing TrnA(B) and all the truncated fragments. In anaerobic conditions, after TrnC 
and TrnD Fe-S clusters reconstitution, TrnC or TrnD, TrnA or TrnB, SAM and sodium dithionite 
were incubated for 3-4 hours at room temperature. The reaction products were analyzed by mass 
spectrometry, but the resulting mixture was too complex to be interpreted. None of the expected 
product or precursor peptide was observed and it was not possible to investigate the nature of the 
peaks (chromatogram not showed). A large amount of the peptide truncated right before the first 
cysteine residue was observed in both cases and seemed to be increased, raising again the 
hypothesis of degradation of the full-length peptide in solution overtime, maybe due to proteases 
carried over from the initial purification. The experiments have to be repeated after successful 
isolation of TrnA and TrnB is accomplished.  
An attempt to observe the crosslink in vivo was also carried out. Co-transformation of pETHSUL-
TrnA and pET-28a(+)-TrnC(D) in E. coli BL21 Star (DE3) cells was successfully accomplished. 
Toxicity of SUMO-Trnα (if the crosslinks were formed) was considered, but the cells grew 
normally and purification of TrnA was carried out. MS analysis resulted in a more complex 
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mixture compared to the purification of SUMO-TrnA, but the detected peptide did not show any 
change in mass and the crosslinked one could not be found. Therefore, even if these experiments 
have to be repeated with more optimal expression conditions, TrnA thioether crosslinks seem not 
to be formed in vivo by either TrnC or TrnD, in aerobic conditions. The only other similar in vivo 
experiment reported was attempted and discussed by Bowers et al.25 for CteA and CteB, without 
any success. 
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Conclusions 
Thuricin CD is the most potent antibiotic against C. difficile known to date. Metronidazole 
and other drugs currently in use strongly alter the microbiota balance in the gut, with dangerous 
side effects. Thuricin CD has been shown to have a potency equivalent to those antibiotics, but 
with far less unspecific activity. It has only been isolated in low amounts from B. thuringiensis, 
and now a larger scale production and advances in clinical trials are needed. For this purpose, 
understanding of the biosynthetic pathway of this natural product is fundamental. Thuricin CD is 
a ribosomally synthesized and post-translational modified bacteriocin, formed by two 30-residue 
subunits, called Trnα and Trnβ. As typical for most RiPPs, thuricin CD is synthesized as two 
precursor peptides, TrnA and TrnB, which undergo a series of enzymatic reactions, ultimately 
leading to the mature, bioactive form. Trnα and Trnβ bear the unique cysteine to α-carbon bond, 
the hallmark of the sactipeptides family. This thioether crosslink is formed through an unknown 
mechanism by sactisynthases, members of the radical S-adenosylmethionine enzyme superfamily. 
Sequence alignment show the presence of two genes encoding two putative sactisynthases in 
thuricin CD operon, called TrnC and TrnD. These enzymes contain the radical SAM motif 
CXXXCXXC, necessary for coordinating a [4Fe-4S]2+ cluster, and several other cysteine residues 
in a SPASM domain, near the C-terminus, which may coordinate another Fe-S cluster, as shown 
for most sactisynthases with similar sequence. After protein expression in iron-enriched media, 
purification and subsequent in vitro reconstitution of the clusters, both enzymes showed the 
presence of at least one [4Fe-4S]2+ cluster. In order to determine the exact number of clusters, site-
directed mutagenesis studies in several different cysteine positions have to be carried out. In vitro 
incubation with iron and sulfur sources could also have resulted in only partial clusters 
reconstitution. TrnC has shown the ability to reduce and cleave SAM, producing 5’-
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deoxyadenosine in the presence of sodium dithionite or titanium(III) citrate. TrnD has not shown 
the same features. This leads to the conclusion that TrnD Fe-S cluster(s) does not get reduced upon 
addition of any of the reducing agents tested, or its activity is dependent on other factors. One 
hypothesis is that addition of the substrate is necessary for activity, or complete reconstitution of 
multiple clusters is needed. Otherwise, the activity could be contingent on the formation of a 
TrnD⦁TrnC complex. EPR spectroscopic analyses will be necessary to provide a better 
understanding of TrnC and TrnD iron-sulfur clusters. 
Expression in E. coli and purification of the precursor peptides TrnA and TrnB was complicated, 
due to their hydrophobicity and small size. Fusion with a Small Ubiquitin-like Modifier protein, 
with subsequent cleavage using an ubiquitin tertiary structure-specific protease rather than a 
sequence-specific one, led to successful isolation of the two peptides. Mass spectrometry spectra 
were acquired, including MS/MS analysis, and the overall result was a very detailed profile of the 
peptide, which will allow precise detection of the thioether crosslinks. However, TrnA and TrnB 
are both subjected to multiple truncations from the C-terminus, resulting in a complex mixture of 
peptides of different size, some of which have been identified. For unknown reasons, the main 
product of this degradation is a peptide truncated at the residue before the first cysteine, for both 
TrnA and TrnB. This phenomenon probably occurs during expression, evidenced by the elongated 
shape of SUMO-TrnA(B) bands on SDS-PAGE. Another more unlikely explanation, could be 
unspecific activity of the SUMO protease. Spontaneous peptide degradation is also possible, since 
the full-length peptide peak slowly decreases overtime, and further attempts in HPLC purification 
failed. Incubation of the degraded peptide mixtures with TrnC and TrnD resulted in MS spectra 
too complicated to be analyzed. Co-expression of SUMO-TrnA and TrnC(D), with subsequent 
purification of the peptides, looking for possible in vivo crosslinking was also attempted. 
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Unfortunately, as previously reported for another sactipeptide, this reaction does not seem to occur 
in aerobic in vivo conditions, and no differences in mass in TrnA were detected. 
In conclusion, TrnC and TrnD purification procedures have been optimized, and preliminary 
characterization data have been collected. TrnA and TrnB, precursor peptides to thuricin CD, have 
been successfully isolated and characterized for the first time. After several attempts in expression 
and purification of the peptides with different fusion partners, the best results were found using a 
N-terminal SUMO fusion protein. Optimization of the process is needed, because product 
degradation is limiting further experiments and analyses. Conditions to initiate TrnC reaction have 
been established; the crosslinks will be detected by comparison of TrnA and TrnB MS spectra 
before and after incubation with TrnC. MS/MS fragments containing cysteine residues will allow 
localization of the crosslinks formed. 
Understanding TrnC and TrnD reactions, followed by the assignment of the roles of each gene in 
thuricin CD gene cluster, will allow the engineering of a production strain, with the final goal of 
pursuing meaningful studies on its activity against Clostridium difficile.  
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